Cefazolin Sodium

Drug overview for CEFAZOLIN SODIUM (cefazolin sodium):

Generic name: CEFAZOLIN SODIUM (sef-A-zoe-lin)
Drug class: Beta-Lactams
Therapeutic class: Anti-Infective Agents

Cefazolin sodium is a semisynthetic, first generation cephalosporin antibiotic.

No enhanced Uses information available for this drug.

DRUG IMAGES

CEFAZOLIN 1 GM VIAL
CEFAZOLIN 500 MG VIAL
CEFAZOLIN 10 GM VIAL
CEFAZOLIN 2 GM VIAL

The following indications for CEFAZOLIN SODIUM (cefazolin sodium) have been approved by the FDA:

Indications:
Bacterial endocarditis
Bacterial pneumonia
Bacterial sepsis
Bacterial urinary tract infection
Biliary tract infection
Bone infection
Genitourinary tract infections
Infectious disorder of joint
Lower respiratory infection
Prevention of perioperative infection
Skin and skin structure infection
Staphylococcal pneumonia
Staphylococcus aureus endocarditis
Streptococcal endocarditis
Streptococcal pneumonia

Professional Synonyms:
Bacteremia with sepsis
Bacterial septicemia
Endocarditis due to S. aureus
Endocarditis due to Staphylococcus aureus
Endocarditis due to Streptococcus
Genitourinary infection
Genitourinary tract infection
Infection of skin and/or subcutaneous tissue
Infective cholangitis
Joint infection
Lower respiratory tract infection
Perioperative infection prophylaxis
Pneumonia due to Staphylococcus species
Pneumonia due to Staphylococcus spp.
Pneumonia due to Streptococcus species
Pneumonia due to Streptococcus spp.
Skin and soft tissue skin infection

The following dosing information is available for CEFAZOLIN SODIUM (cefazolin sodium):

Dosing
Administration
CEFAZOLIN SODIUM
CEFAZOLIN SODIUM

Dosage of cefazolin sodium is expressed in terms of cefazolin and is identical for IM or IV administration.

To avoid unintentional overdosage, the commercially available Duplex(R) drug delivery system containing cefazolin and dextrose injection and the commercially available frozen premixed cefazolin injection in dextrose should not be used in patients who require less than the entire 1- or 2-g dose in the container.

The usual adult dosage of cefazolin for the treatment of mild infections caused by susceptible gram-positive cocci is 250-500 mg every 8 hours.

The usual adult dosage of cefazolin for the treatment of moderate to severe infections is 0.5-1 g every 6-8 hours.

The usual adult dosage of cefazolin for the treatment of severe, life-threatening infections (e.g., endocarditis, septicemia) is 1-1.5 g every 6 hours. In rare instances, up to 12 g daily has been used.

The manufacturers state that safety and efficacy of cefazolin have not been established in premature infants or neonates 1 month of age or younger.

The American Academy of Pediatrics (AAP) recommends that neonates 7 days of age or younger+ receive IV or IM cefazolin in a dosage of 25 mg/kg every 12 hours, regardless of weight. For neonates 8-28 days of age+, the AAP recommends a dosage of 25 mg/kg every 12 hours for those weighing 2 kg or less and 25 mg/kg every 8 hours for those weighing more than 2 kg.

The usual dosage of cefazolin recommended by the manufacturers for the treatment of mild to moderately severe infections in pediatric patients older than 1 month of age is 25-50 mg/kg daily given in 3 or 4 equally divided doses. The manufacturers state that dosage may be increased to 100 mg/kg daily in divided doses for the treatment of severe infections.

The AAP recommends that pediatric patients beyond the neonatal period receive IV or IM cefazolin in a dosage of 25-50 mg/kg daily given in 3 equally divided doses for the treatment of mild to moderate infections or 100-150 mg/kg daily given in 3 equally divided doses for the treatment of severe infections.

In patients with impaired renal function, doses and/or frequency of administration of cefazolin must be modified in response to the degree of impairment, severity of the infection, susceptibility of the causative organism, and serum concentrations of the drug.

The manufacturers recommend an initial loading dose appropriate for the severity of the infection followed by dosage based on the degree of renal impairment. (See Table 1 and Table 2.)

Table 1. Dosage for Adults with Renal Impairment

Creatinine Clearance (mL/minute) Dosage After Initial Loading Dose 35-54 Full doses at intervals >=8 hours 11-34 50% of usual dose every 12 hours <=10 50% of usual dose every 18-24 hours

Table 2. Dosage for Children Older than 1 Month of Age with Renal Impairment

Creatinine Clearance (mL/minute) Dosage After Initial Loading Dose 40-70 60% of usual daily dosage in divided doses every 12 hours 20-40 25% of usual daily dosage in divided doses every 12 hours 5-20 10% of usual daily dosage once every 24 hours

No enhanced Administration information available for this drug.

Dosing information for CEFAZOLIN SODIUM
DRUG LABEL	DOSING TYPE	DOSING INSTRUCTIONS
CEFAZOLIN 1 GM VIAL	Maintenance	Adults inject 1 gram by intravenous route every 8 hours
CEFAZOLIN 500 MG VIAL	Maintenance	Adults inject 1 gram by intravenous route every 8 hours
CEFAZOLIN 10 GM VIAL	Maintenance	Adults inject 1 gram by intravenous route every 8 hours
CEFAZOLIN 2 GM VIAL	Maintenance	Adults inject 2 gram by intravenous route every 8 hours
CEFAZOLIN 3 GM VIAL	Maintenance	Adults inject 2 gram by intravenous route every 8 hours

Generic dosing information for CEFAZOLIN SODIUM
DRUG LABEL	DOSING TYPE	DOSING INSTRUCTIONS
CEFAZOLIN 2 GM VIAL	Maintenance	Adults inject 2 gram by intravenous route every 8 hours
CEFAZOLIN 3 GM VIAL	Maintenance	Adults inject 2 gram by intravenous route every 8 hours
CEFAZOLIN 10 GM VIAL	Maintenance	Adults inject 1 gram by intravenous route every 8 hours
CEFAZOLIN 1 GM VIAL	Maintenance	Adults inject 1 gram by intravenous route every 8 hours
CEFAZOLIN 500 MG VIAL	Maintenance	Adults inject 1 gram by intravenous route every 8 hours

The following drug interaction information is available for CEFAZOLIN SODIUM (cefazolin sodium):

Contraindicated
Severe
Moderate

There are 1 contraindications. These drug combinations generally should not be dispensed or administered to the same patient. A manufacturer label warning that indicates the contraindication warrants inclusion of a drug combination in this category, regardless of clinical evidence or lack of clinical evidence to support the contraindication.

Drug Interaction	Drug Names
Live Typhoid Vaccine/Antimicrobials SEVERITY LEVEL: 1-Contraindicated Drug Combination: This drug combination is contraindicated and generally should not be dispensed or administered to the same patient. MECHANISM OF ACTION: The antimicrobial may be active against the organism in the live-vaccine. Antimicrobial therapy may prevent the vaccine organism from replicating enough to trigger an immune response.(1) CLINICAL EFFECTS: Vaccination may be ineffective. PREDISPOSING FACTORS: None determined. PATIENT MANAGEMENT: Do not give oral typhoid vaccine until 72 hours after the last dose of antimicrobial. If possible, to optimize vaccine effectiveness, do not start antibacterial drugs for 72 hours after the last dose of oral typhoid vaccine. A longer interval should be considered for long-acting antimicrobials, such as azithromycin.(3) DISCUSSION: Because antimicrobial therapy may prevent sufficient vaccine-organism replication to generate an immune response, the manufacturer of live-attenuated typhoid vaccine and the Centers for Disease Control (CDC) state that the vaccine should not be administered to patients receiving antimicrobial therapy.(1-3)	VIVOTIF

Drug Interaction

Drug Names

Live Typhoid Vaccine/Antimicrobials

SEVERITY LEVEL: 1-Contraindicated Drug Combination: This drug combination is contraindicated and generally should not be dispensed or administered to the same patient.

MECHANISM OF ACTION: The antimicrobial may be active against the organism in the live-vaccine. Antimicrobial therapy may prevent the vaccine organism from replicating enough to trigger an immune response.(1)

CLINICAL EFFECTS: Vaccination may be ineffective.

PREDISPOSING FACTORS: None determined.

PATIENT MANAGEMENT: Do not give oral typhoid vaccine until 72 hours after the last dose of antimicrobial. If possible, to optimize vaccine effectiveness, do not start antibacterial drugs for 72 hours after the last dose of oral typhoid vaccine. A longer interval should be considered for long-acting antimicrobials, such as azithromycin.(3)

DISCUSSION: Because antimicrobial therapy may prevent sufficient vaccine-organism replication to generate an immune response, the manufacturer of live-attenuated typhoid vaccine and the Centers for Disease Control (CDC) state that the vaccine should not be administered to patients receiving antimicrobial therapy.(1-3)

VIVOTIF

There are 1 severe interactions. These drug interactions can produce serious consequences in most patients. Actions required for severe interactions include, but are not limited to, discontinuing one or both agents, adjusting dosage, altering administration scheduling, and providing additional patient monitoring. Review the full interaction monograph for more information.

Drug Interaction	Drug Names
Fecal Microbiota Spores/Antibiotics SEVERITY LEVEL: 2-Severe Interaction: Action is required to reduce the risk of severe adverse interaction. MECHANISM OF ACTION: Fecal microbiota spores is a suspension of live bacterial spores, which may be compromised by concurrent use of antibiotics.(1) CLINICAL EFFECTS: Antibiotics may decrease the effectiveness of fecal microbiota spores.(1) PREDISPOSING FACTORS: None determined. PATIENT MANAGEMENT: Antibiotics should not be used concurrently with fecal microbiota spores. Antibacterial treatment should be completed for 2 to 4 days before initiating treatment with fecal microbiota spores.(1) DISCUSSION: Antibiotics may compromise the effectiveness of fecal microbiota spores.	VOWST

Drug Interaction

Drug Names

Fecal Microbiota Spores/Antibiotics

SEVERITY LEVEL: 2-Severe Interaction: Action is required to reduce the risk of severe adverse interaction.

MECHANISM OF ACTION: Fecal microbiota spores is a suspension of live bacterial spores, which may be compromised by concurrent use of antibiotics.(1)

CLINICAL EFFECTS: Antibiotics may decrease the effectiveness of fecal microbiota spores.(1)

PREDISPOSING FACTORS: None determined.

PATIENT MANAGEMENT: Antibiotics should not be used concurrently with fecal microbiota spores. Antibacterial treatment should be completed for 2 to 4 days before initiating treatment with fecal microbiota spores.(1)

DISCUSSION: Antibiotics may compromise the effectiveness of fecal microbiota spores.

VOWST

There are 2 moderate interactions. The clinician should assess the patient’s characteristics and take action as needed. Actions required for moderate interactions include, but are not limited to, discontinuing one or both agents, adjusting dosage, altering administration.

Drug Interaction	Drug Names
Selected Cephalosporins & Penicillins/Probenecid SEVERITY LEVEL: 3-Moderate Interaction: Assess the risk to the patient and take action as needed. MECHANISM OF ACTION: Probenecid impairs the clearance of some cephalosporins and penicillins via inhibition of renal anion transporters in the proximal tubule.(49) It has also been hypothesized that probenecid may affect tissue distribution of cephalosporins.(1-5) CLINICAL EFFECTS: The concurrent administration of probenecid may result in increased maximum concentration (Cmax), area-under-curve (AUC), and half-life of the cephalosporin or penicillin.(49) While this may improve antibiotic efficacy,(46-48) increased levels may also increase the risk for antibiotic-associated nephrotoxicity.(4) PREDISPOSING FACTORS: Underlying renal dysfunction may increase the risk for nephrotoxicity. PATIENT MANAGEMENT: In patients receiving the combination to improve antibiotic efficacy, monitor for antibiotic adverse effects and consider monitoring renal function. In patients receiving probenecid therapy to prevent or treat hyperuricemia, exposure to the antibiotic will be increased. A decrease in antibiotic dose or frequency may be required. The US manufacturer of piperacillin-tazobactam states probenecid should not be coadministered with piperacillin-tazobactam unless the benefit outweighs the risk.(50) DISCUSSION: Concurrent use of probenecid with a cephalosporin or penicillin may cause an increase in the Cmax, AUC, and an increased elimination half life of the antibiotic.(6-8,49) This may be beneficial or necessary in difficult to treat infections,(46-48) but an increased risk for adverse effects should be expected. Antibiotics not dose adjusted for concurrent use with probenecid may be associated with an increased risk for adverse effects, such as nephrotoxicity. Probenecid administered concurrently with piperacillin-tazobactam prolongs the half-life of piperacillin by 21% and tazobactam by 71%. In a study in 8 healthy males, concurrent administration of probenecid (1 g) with piperacillin (1 g IM) increased piperacillin's Cmax and AUC by 30% and 60%. Renal clearance was reduced by 40%.(51) The cephalosporins affected by probenecid include cefazolin,(9-11) cephacetrile,(12,13) cephaloglycin,(14,15) cephalexin,(16-21) cephradine, (22-23) cefoxitin,(24-28) cefadroxil(29), cefaclor,(23) cefamandole,(30) ceftizoxime,(31,32) cefuroxime,(33,34) cefprozil,(35) cefonicid,(36) cefmetazole,(37) cefmenoxime,(38) and cefditoren.(39) Probenecid has been shown not to affect moxalactam,(4,40,41) ceforanide, (4,42), cefoperazone, ceftazidime(4,34,43) or ceftriaxone.(4)	PROBENECID, PROBENECID-COLCHICINE
Slt Anticoagulants (Vit K antagonists)/Slt Cephalosporins SEVERITY LEVEL: 3-Moderate Interaction: Assess the risk to the patient and take action as needed. MECHANISM OF ACTION: The exact mechanism is unknown, but may involve a combination of cephalosporin induced platelet inhibition and alteration of gut flora. CLINICAL EFFECTS: Concurrent use of some cephalosporins may increase the hypoprothrombinemic effect of the anticoagulant with possible bleeding. PREDISPOSING FACTORS: High doses, hepatic and/or renal impairment, and poor nutrition may increase the risk of bleeding. The risk for bleeding episodes may be greater in patients with disease-associated factors (e.g. thrombocytopenia). Drug associated risk factors include concurrent use of multiple drugs which inhibit anticoagulant/antiplatelet metabolism and/or have an inherent risk for bleeding (e.g. NSAIDs). PATIENT MANAGEMENT: Monitor prothrombin activity and adjust the anticoagulant dosage accordingly. Consider using an alternative antibiotic. If concurrent therapy is warranted, monitor patients receiving concurrent therapy for signs of blood loss, including decreased hemoglobin, hematocrit, fecal occult blood, and/or decreased blood pressure and promptly evaluate patients with any symptoms. When applicable, perform agent-specific laboratory test (e.g. INR, aPTT) to monitor efficacy and safety of anticoagulation. Discontinue anticoagulation in patients with active pathologic bleeding. Instruct patients to report any signs and symptoms of bleeding, such as unusual bleeding from the gums or nose; unusual bruising; red or black, tarry stools; red, pink or dark brown urine; acute abdominal or joint pain and/or swelling. The time of highest risk for a coumarin-type drug interaction is when the precipitant drug is initiated or discontinued. Contact the prescriber before initiating, altering the dose or discontinuing either drug. DISCUSSION: Although the majority of cephalosporins that have been documented to interact with anticoagulants have a NMTT side chain, there are reports of interactions with cefazolin, cefoxitin, ceftaroline, and ceftriaxone as well. The time of highest risk for a coumarin-type drug interaction is when the precipitant drug is initiated or discontinued. A large systematic review was performed on 72 warfarin drug-drug interactions studies that reported on bleeding, thromboembolic events, or death. Most studies were retrospective cohorts. A meta-analysis of 11 of those studies found a higher rate of clinically significant bleeding in patients on warfarin and antimicrobials (OR=1.63; 95% CI 1.45-1.83). Increased bleeding risk was also seen in subgroup analyses with cephalosporins (OR=1.50; 95% CI 1.21-1.86).	ANISINDIONE, DICUMAROL, JANTOVEN, PHENINDIONE, WARFARIN SODIUM

Drug Interaction

Drug Names

Selected Cephalosporins & Penicillins/Probenecid

SEVERITY LEVEL: 3-Moderate Interaction: Assess the risk to the patient and take action as needed.

MECHANISM OF ACTION: Probenecid impairs the clearance of some cephalosporins and penicillins via inhibition of renal anion transporters in the proximal tubule.(49) It has also been hypothesized that probenecid may affect tissue distribution of cephalosporins.(1-5)

CLINICAL EFFECTS: The concurrent administration of probenecid may result in increased maximum concentration (Cmax), area-under-curve (AUC), and half-life of the cephalosporin or penicillin.(49) While this may improve antibiotic efficacy,(46-48) increased levels may also increase the risk for antibiotic-associated nephrotoxicity.(4)

PREDISPOSING FACTORS: Underlying renal dysfunction may increase the risk for nephrotoxicity.

PATIENT MANAGEMENT: In patients receiving the combination to improve antibiotic efficacy, monitor for antibiotic adverse effects and consider monitoring renal function. In patients receiving probenecid therapy to prevent or treat hyperuricemia, exposure to the antibiotic will be increased. A decrease in antibiotic dose or frequency may be required. The US manufacturer of piperacillin-tazobactam states probenecid should not be coadministered with piperacillin-tazobactam unless the benefit outweighs the risk.(50)

DISCUSSION: Concurrent use of probenecid with a cephalosporin or penicillin may cause an increase in the Cmax, AUC, and an increased elimination half life of the antibiotic.(6-8,49) This may be beneficial or necessary in difficult to treat infections,(46-48) but an increased risk for adverse effects should be expected. Antibiotics not dose adjusted for concurrent use with probenecid may be associated with an increased risk for adverse effects, such as nephrotoxicity.

Probenecid administered concurrently with piperacillin-tazobactam prolongs the half-life of piperacillin by 21% and tazobactam by 71%. In a study in 8 healthy males, concurrent administration of probenecid (1 g) with piperacillin (1 g IM) increased piperacillin's Cmax and AUC by 30% and 60%. Renal clearance was reduced by 40%.(51)

The cephalosporins affected by probenecid include cefazolin,(9-11) cephacetrile,(12,13) cephaloglycin,(14,15) cephalexin,(16-21) cephradine, (22-23) cefoxitin,(24-28) cefadroxil(29), cefaclor,(23) cefamandole,(30) ceftizoxime,(31,32) cefuroxime,(33,34) cefprozil,(35) cefonicid,(36) cefmetazole,(37) cefmenoxime,(38) and cefditoren.(39) Probenecid has been shown not to affect moxalactam,(4,40,41) ceforanide, (4,42), cefoperazone, ceftazidime(4,34,43) or ceftriaxone.(4)

PROBENECID, PROBENECID-COLCHICINE

Slt Anticoagulants (Vit K antagonists)/Slt Cephalosporins

SEVERITY LEVEL: 3-Moderate Interaction: Assess the risk to the patient and take action as needed.

MECHANISM OF ACTION: The exact mechanism is unknown, but may involve a combination of cephalosporin induced platelet inhibition and alteration of gut flora.

CLINICAL EFFECTS: Concurrent use of some cephalosporins may increase the hypoprothrombinemic effect of the anticoagulant with possible bleeding.

PREDISPOSING FACTORS: High doses, hepatic and/or renal impairment, and poor nutrition may increase the risk of bleeding. The risk for bleeding episodes may be greater in patients with disease-associated factors (e.g. thrombocytopenia). Drug associated risk factors include concurrent use of multiple drugs which inhibit anticoagulant/antiplatelet metabolism and/or have an inherent risk for bleeding (e.g. NSAIDs).

PATIENT MANAGEMENT: Monitor prothrombin activity and adjust the anticoagulant dosage accordingly. Consider using an alternative antibiotic. If concurrent therapy is warranted, monitor patients receiving concurrent therapy for signs of blood loss, including decreased hemoglobin, hematocrit, fecal occult blood, and/or decreased blood pressure and promptly evaluate patients with any symptoms.

When applicable, perform agent-specific laboratory test (e.g. INR, aPTT) to monitor efficacy and safety of anticoagulation. Discontinue anticoagulation in patients with active pathologic bleeding. Instruct patients to report any signs and symptoms of bleeding, such as unusual bleeding from the gums or nose; unusual bruising; red or black, tarry stools; red, pink or dark brown urine; acute abdominal or joint pain and/or swelling.

The time of highest risk for a coumarin-type drug interaction is when the precipitant drug is initiated or discontinued. Contact the prescriber before initiating, altering the dose or discontinuing either drug.

DISCUSSION: Although the majority of cephalosporins that have been documented to interact with anticoagulants have a NMTT side chain, there are reports of interactions with cefazolin, cefoxitin, ceftaroline, and ceftriaxone as well. The time of highest risk for a coumarin-type drug interaction is when the precipitant drug is initiated or discontinued. A large systematic review was performed on 72 warfarin drug-drug interactions studies that reported on bleeding, thromboembolic events, or death.

Most studies were retrospective cohorts. A meta-analysis of 11 of those studies found a higher rate of clinically significant bleeding in patients on warfarin and antimicrobials (OR=1.63; 95% CI 1.45-1.83). Increased bleeding risk was also seen in subgroup analyses with cephalosporins (OR=1.50; 95% CI 1.21-1.86).

ANISINDIONE, DICUMAROL, JANTOVEN, PHENINDIONE, WARFARIN SODIUM

The following contraindication information is available for CEFAZOLIN SODIUM (cefazolin sodium):

Overview
Contraindicated
Severe
Moderate

Drug contraindication overview.

No enhanced Contraindications information available for this drug.

There are 0 contraindications.

There are 6 severe contraindications. Adequate patient monitoring is recommended for safer drug use.

Severe List
Chronic kidney disease stage 2 (mild) GFR 60-89 ml/min
Chronic kidney disease stage 3A (moderate) GFR 45-59 ml/min
Chronic kidney disease stage 3B (moderate) GFR 30-44 ml/min
Chronic kidney disease stage 4 (severe) GFR 15-29 ml/min
Chronic kidney disease stage 5 (failure) GFr<15 ml/min
Clostridioides difficile infection

There are 1 moderate contraindications. Clinically significant contraindication, where the condition can be managed or treated before the drug may be given safely.

Moderate List
Hypoprothrombinemia

The following adverse reaction information is available for CEFAZOLIN SODIUM (cefazolin sodium):

Overview
Severe
Less Severe

Adverse reaction overview.

No enhanced Common Adverse Effects information available for this drug.

There are 35 severe adverse reactions.

More Frequent	Less Frequent
None.	None.

Rare/Very Rare
Abnormal hepatic function tests Acute generalized exanthematous pustulosis Agranulocytosis Anaphylaxis Angioedema Aplastic anemia Candidiasis Cholestasis Clostridioides difficile infection Colitis DRESS syndrome Eosinophilia Erythema multiforme Hallucinations Hemolytic anemia Hemorrhage Hepatitis Hyperbilirubinemia Hypersensitivity drug reaction Hypoprothrombinemia Interstitial nephritis Jaundice Kidney disease with reduction in glomerular filtration rate (GFr) Myoclonus Obstructive hyperbilirubinemia Pancytopenia Pemphigus Pruritus of skin Renal failure Seizure disorder Serum sickness Stevens-johnson syndrome Thrombocytopenic disorder Toxic epidermal necrolysis Urticaria

Rare/Very Rare

Abnormal hepatic function tests
Acute generalized exanthematous pustulosis
Agranulocytosis
Anaphylaxis
Angioedema
Aplastic anemia
Candidiasis
Cholestasis
Clostridioides difficile infection
Colitis
DRESS syndrome
Eosinophilia
Erythema multiforme
Hallucinations
Hemolytic anemia
Hemorrhage
Hepatitis
Hyperbilirubinemia
Hypersensitivity drug reaction
Hypoprothrombinemia
Interstitial nephritis
Jaundice
Kidney disease with reduction in glomerular filtration rate (GFr)
Myoclonus
Obstructive hyperbilirubinemia
Pancytopenia
Pemphigus
Pruritus of skin
Renal failure
Seizure disorder
Serum sickness
Stevens-johnson syndrome
Thrombocytopenic disorder
Toxic epidermal necrolysis
Urticaria

There are 20 less severe adverse reactions.

More Frequent	Less Frequent
Acute abdominal pain Diarrhea Dyspepsia Nausea Vomiting	Gastritis Vulvovaginal candidiasis

Rare/Very Rare
Acute cognitive impairment Agitation Arthralgia Dizziness Drug fever Fatigue Genital organ pruritus Headache disorder Paresthesia Phlebitis after infusion Pruritus ani Skin rash Vaginitis

The following precautions are available for CEFAZOLIN SODIUM (cefazolin sodium):

Pediatric
Pregnant
Lactation
Geriatric

No enhanced Pediatric Use information available for this drug.

Contraindicated

None

Severe Precaution

None

Management or Monitoring Precaution

None

No enhanced Pregnancy information available for this drug.

No enhanced Lactation information available for this drug.

No enhanced Geriatric Use information available for this drug.

The following icd codes are available for CEFAZOLIN SODIUM (cefazolin sodium)'s list of indications:

Bacterial endocarditis
I33.0	Acute and subacute infective endocarditis
Bacterial pneumonia
J15.9	Unspecified bacterial pneumonia
Bacterial sepsis
A02.1	Salmonella sepsis
A20.7	Septicemic plague
A22.7	Anthrax sepsis
A26.7	Erysipelothrix sepsis
A32.7	Listerial sepsis
A40	Streptococcal sepsis
A40.0	Sepsis due to streptococcus, group A
A40.1	Sepsis due to streptococcus, group B
A40.3	Sepsis due to streptococcus pneumoniae
A40.8	Other streptococcal sepsis
A40.9	Streptococcal sepsis, unspecified
A41	Other sepsis
A41.0	Sepsis due to staphylococcus aureus
A41.01	Sepsis due to methicillin susceptible staphylococcus aureus
A41.02	Sepsis due to methicillin resistant staphylococcus aureus
A41.1	Sepsis due to other specified staphylococcus
A41.2	Sepsis due to unspecified staphylococcus
A41.3	Sepsis due to hemophilus influenzae
A41.4	Sepsis due to anaerobes
A41.5	Sepsis due to other gram-negative organisms
A41.50	Gram-negative sepsis, unspecified
A41.51	Sepsis due to escherichia coli [e. coli]
A41.52	Sepsis due to pseudomonas
A41.53	Sepsis due to serratia
A41.54	Sepsis due to acinetobacter baumannii
A41.59	Other gram-negative sepsis
A41.8	Other specified sepsis
A41.81	Sepsis due to enterococcus
A41.89	Other specified sepsis
A41.9	Sepsis, unspecified organism
A42.7	Actinomycotic sepsis
A54.86	Gonococcal sepsis
O03.37	Sepsis following incomplete spontaneous abortion
O08.82	Sepsis following ectopic and molar pregnancy
O85	Puerperal sepsis
O86.04	Sepsis following an obstetrical procedure
P36	Bacterial sepsis of newborn
P36.0	Sepsis of newborn due to streptococcus, group B
P36.1	Sepsis of newborn due to other and unspecified streptococci
P36.10	Sepsis of newborn due to unspecified streptococci
P36.19	Sepsis of newborn due to other streptococci
P36.2	Sepsis of newborn due to staphylococcus aureus
P36.3	Sepsis of newborn due to other and unspecified staphylococci
P36.30	Sepsis of newborn due to unspecified staphylococci
P36.39	Sepsis of newborn due to other staphylococci
P36.4	Sepsis of newborn due to escherichia coli
P36.5	Sepsis of newborn due to anaerobes
P36.8	Other bacterial sepsis of newborn
P36.9	Bacterial sepsis of newborn, unspecified
R65.2	Severe sepsis
T81.12	Postprocedural septic shock
T81.12xA	Postprocedural septic shock, initial encounter
T81.44	Sepsis following a procedure
T81.44xA	Sepsis following a procedure, initial encounter
Bacterial urinary tract infection
N30.0	Acute cystitis
N30.00	Acute cystitis without hematuria
N30.01	Acute cystitis with hematuria
N30.9	Cystitis, unspecified
N30.90	Cystitis, unspecified without hematuria
N30.91	Cystitis, unspecified with hematuria
N39.0	Urinary tract infection, site not specified
O23.0	Infections of kidney in pregnancy
O23.00	Infections of kidney in pregnancy, unspecified trimester
O23.01	Infections of kidney in pregnancy, first trimester
O23.02	Infections of kidney in pregnancy, second trimester
O23.03	Infections of kidney in pregnancy, third trimester
O23.1	Infections of bladder in pregnancy
O23.10	Infections of bladder in pregnancy, unspecified trimester
O23.11	Infections of bladder in pregnancy, first trimester
O23.12	Infections of bladder in pregnancy, second trimester
O23.13	Infections of bladder in pregnancy, third trimester
O23.2	Infections of urethra in pregnancy
O23.20	Infections of urethra in pregnancy, unspecified trimester
O23.21	Infections of urethra in pregnancy, first trimester
O23.22	Infections of urethra in pregnancy, second trimester
O23.23	Infections of urethra in pregnancy, third trimester
O23.3	Infections of other parts of urinary tract in pregnancy
O23.30	Infections of other parts of urinary tract in pregnancy, unspecified trimester
O23.31	Infections of other parts of urinary tract in pregnancy, first trimester
O23.32	Infections of other parts of urinary tract in pregnancy, second trimester
O23.33	Infections of other parts of urinary tract in pregnancy, third trimester
O23.4	Unspecified infection of urinary tract in pregnancy
O23.40	Unspecified infection of urinary tract in pregnancy, unspecified trimester
O23.41	Unspecified infection of urinary tract in pregnancy, first trimester
O23.42	Unspecified infection of urinary tract in pregnancy, second trimester
O23.43	Unspecified infection of urinary tract in pregnancy, third trimester
O23.90	Unspecified genitourinary tract infection in pregnancy, unspecified trimester
O23.91	Unspecified genitourinary tract infection in pregnancy, first trimester
O23.92	Unspecified genitourinary tract infection in pregnancy, second trimester
O23.93	Unspecified genitourinary tract infection in pregnancy, third trimester
P39.3	Neonatal urinary tract infection
T83	Complications of genitourinary prosthetic devices, implants and grafts
T83.5	Infection and inflammatory reaction due to prosthetic device, implant and graft in urinary system
T83.51	Infection and inflammatory reaction due to urinary catheter
T83.59	Infection and inflammatory reaction due to prosthetic device, implant and graft in urinary system
T83.6	Infection and inflammatory reaction due to prosthetic device, implant and graft in genital tract
Biliary tract infection
K83.0	Cholangitis
K83.09	Other cholangitis
Bone infection
H05.02	Osteomyelitis of orbit
H05.021	Osteomyelitis of right orbit
H05.022	Osteomyelitis of left orbit
H05.023	Osteomyelitis of bilateral orbits
H05.029	Osteomyelitis of unspecified orbit
H70	Mastoiditis and related conditions
H70.0	Acute mastoiditis
H70.00	Acute mastoiditis without complications
H70.001	Acute mastoiditis without complications, right ear
H70.002	Acute mastoiditis without complications, left ear
H70.003	Acute mastoiditis without complications, bilateral
H70.009	Acute mastoiditis without complications, unspecified ear
H70.01	Subperiosteal abscess of mastoid
H70.011	Subperiosteal abscess of mastoid, right ear
H70.012	Subperiosteal abscess of mastoid, left ear
H70.013	Subperiosteal abscess of mastoid, bilateral
H70.019	Subperiosteal abscess of mastoid, unspecified ear
H70.09	Acute mastoiditis with other complications
H70.091	Acute mastoiditis with other complications, right ear
H70.092	Acute mastoiditis with other complications, left ear
H70.093	Acute mastoiditis with other complications, bilateral
H70.099	Acute mastoiditis with other complications, unspecified ear
H70.1	Chronic mastoiditis
H70.10	Chronic mastoiditis, unspecified ear
H70.11	Chronic mastoiditis, right ear
H70.12	Chronic mastoiditis, left ear
H70.13	Chronic mastoiditis, bilateral
H70.2	Petrositis
H70.20	Unspecified petrositis
H70.201	Unspecified petrositis, right ear
H70.202	Unspecified petrositis, left ear
H70.203	Unspecified petrositis, bilateral
H70.209	Unspecified petrositis, unspecified ear
H70.21	Acute petrositis
H70.211	Acute petrositis, right ear
H70.212	Acute petrositis, left ear
H70.213	Acute petrositis, bilateral
H70.219	Acute petrositis, unspecified ear
H70.22	Chronic petrositis
H70.221	Chronic petrositis, right ear
H70.222	Chronic petrositis, left ear
H70.223	Chronic petrositis, bilateral
H70.229	Chronic petrositis, unspecified ear
H70.8	Other mastoiditis and related conditions
H70.89	Other mastoiditis and related conditions
H70.891	Other mastoiditis and related conditions, right ear
H70.892	Other mastoiditis and related conditions, left ear
H70.893	Other mastoiditis and related conditions, bilateral
H70.899	Other mastoiditis and related conditions, unspecified ear
H70.9	Unspecified mastoiditis
H70.90	Unspecified mastoiditis, unspecified ear
H70.91	Unspecified mastoiditis, right ear
H70.92	Unspecified mastoiditis, left ear
H70.93	Unspecified mastoiditis, bilateral
H75.0	Mastoiditis in infectious and parasitic diseases classified elsewhere
H75.00	Mastoiditis in infectious and parasitic diseases classified elsewhere, unspecified ear
H75.01	Mastoiditis in infectious and parasitic diseases classified elsewhere, right ear
H75.02	Mastoiditis in infectious and parasitic diseases classified elsewhere, left ear
H75.03	Mastoiditis in infectious and parasitic diseases classified elsewhere, bilateral
M46.2	Osteomyelitis of vertebra
M46.20	Osteomyelitis of vertebra, site unspecified
M46.21	Osteomyelitis of vertebra, occipito-atlanto-axial region
M46.22	Osteomyelitis of vertebra, cervical region
M46.23	Osteomyelitis of vertebra, cervicothoracic region
M46.24	Osteomyelitis of vertebra, thoracic region
M46.25	Osteomyelitis of vertebra, thoracolumbar region
M46.26	Osteomyelitis of vertebra, lumbar region
M46.27	Osteomyelitis of vertebra, lumbosacral region
M46.28	Osteomyelitis of vertebra, sacral and sacrococcygeal region
M46.5	Other infective spondylopathies
M46.50	Other infective spondylopathies, site unspecified
M46.51	Other infective spondylopathies, occipito-atlanto-axial region
M46.52	Other infective spondylopathies, cervical region
M46.53	Other infective spondylopathies, cervicothoracic region
M46.54	Other infective spondylopathies, thoracic region
M46.55	Other infective spondylopathies, thoracolumbar region
M46.56	Other infective spondylopathies, lumbar region
M46.57	Other infective spondylopathies, lumbosacral region
M46.58	Other infective spondylopathies, sacral and sacrococcygeal region
M46.59	Other infective spondylopathies, multiple sites in spine
M86	Osteomyelitis
M86.0	Acute hematogenous osteomyelitis
M86.00	Acute hematogenous osteomyelitis, unspecified site
M86.01	Acute hematogenous osteomyelitis, shoulder
M86.011	Acute hematogenous osteomyelitis, right shoulder
M86.012	Acute hematogenous osteomyelitis, left shoulder
M86.019	Acute hematogenous osteomyelitis, unspecified shoulder
M86.02	Acute hematogenous osteomyelitis, humerus
M86.021	Acute hematogenous osteomyelitis, right humerus
M86.022	Acute hematogenous osteomyelitis, left humerus
M86.029	Acute hematogenous osteomyelitis, unspecified humerus
M86.03	Acute hematogenous osteomyelitis, radius and ulna
M86.031	Acute hematogenous osteomyelitis, right radius and ulna
M86.032	Acute hematogenous osteomyelitis, left radius and ulna
M86.039	Acute hematogenous osteomyelitis, unspecified radius and ulna
M86.04	Acute hematogenous osteomyelitis, hand
M86.041	Acute hematogenous osteomyelitis, right hand
M86.042	Acute hematogenous osteomyelitis, left hand
M86.049	Acute hematogenous osteomyelitis, unspecified hand
M86.05	Acute hematogenous osteomyelitis, femur
M86.051	Acute hematogenous osteomyelitis, right femur
M86.052	Acute hematogenous osteomyelitis, left femur
M86.059	Acute hematogenous osteomyelitis, unspecified femur
M86.06	Acute hematogenous osteomyelitis, tibia and fibula
M86.061	Acute hematogenous osteomyelitis, right tibia and fibula
M86.062	Acute hematogenous osteomyelitis, left tibia and fibula
M86.069	Acute hematogenous osteomyelitis, unspecified tibia and fibula
M86.07	Acute hematogenous osteomyelitis, ankle and foot
M86.071	Acute hematogenous osteomyelitis, right ankle and foot
M86.072	Acute hematogenous osteomyelitis, left ankle and foot
M86.079	Acute hematogenous osteomyelitis, unspecified ankle and foot
M86.08	Acute hematogenous osteomyelitis, other sites
M86.09	Acute hematogenous osteomyelitis, multiple sites
M86.1	Other acute osteomyelitis
M86.10	Other acute osteomyelitis, unspecified site
M86.11	Other acute osteomyelitis, shoulder
M86.111	Other acute osteomyelitis, right shoulder
M86.112	Other acute osteomyelitis, left shoulder
M86.119	Other acute osteomyelitis, unspecified shoulder
M86.12	Other acute osteomyelitis, humerus
M86.121	Other acute osteomyelitis, right humerus
M86.122	Other acute osteomyelitis, left humerus
M86.129	Other acute osteomyelitis, unspecified humerus
M86.13	Other acute osteomyelitis, radius and ulna
M86.131	Other acute osteomyelitis, right radius and ulna
M86.132	Other acute osteomyelitis, left radius and ulna
M86.139	Other acute osteomyelitis, unspecified radius and ulna
M86.14	Other acute osteomyelitis, hand
M86.141	Other acute osteomyelitis, right hand
M86.142	Other acute osteomyelitis, left hand
M86.149	Other acute osteomyelitis, unspecified hand
M86.15	Other acute osteomyelitis, femur
M86.151	Other acute osteomyelitis, right femur
M86.152	Other acute osteomyelitis, left femur
M86.159	Other acute osteomyelitis, unspecified femur
M86.16	Other acute osteomyelitis, tibia and fibula
M86.161	Other acute osteomyelitis, right tibia and fibula
M86.162	Other acute osteomyelitis, left tibia and fibula
M86.169	Other acute osteomyelitis, unspecified tibia and fibula
M86.17	Other acute osteomyelitis, ankle and foot
M86.171	Other acute osteomyelitis, right ankle and foot
M86.172	Other acute osteomyelitis, left ankle and foot
M86.179	Other acute osteomyelitis, unspecified ankle and foot
M86.18	Other acute osteomyelitis, other site
M86.19	Other acute osteomyelitis, multiple sites
M86.2	Subacute osteomyelitis
M86.20	Subacute osteomyelitis, unspecified site
M86.21	Subacute osteomyelitis, shoulder
M86.211	Subacute osteomyelitis, right shoulder
M86.212	Subacute osteomyelitis, left shoulder
M86.219	Subacute osteomyelitis, unspecified shoulder
M86.22	Subacute osteomyelitis, humerus
M86.221	Subacute osteomyelitis, right humerus
M86.222	Subacute osteomyelitis, left humerus
M86.229	Subacute osteomyelitis, unspecified humerus
M86.23	Subacute osteomyelitis, radius and ulna
M86.231	Subacute osteomyelitis, right radius and ulna
M86.232	Subacute osteomyelitis, left radius and ulna
M86.239	Subacute osteomyelitis, unspecified radius and ulna
M86.24	Subacute osteomyelitis, hand
M86.241	Subacute osteomyelitis, right hand
M86.242	Subacute osteomyelitis, left hand
M86.249	Subacute osteomyelitis, unspecified hand
M86.25	Subacute osteomyelitis, femur
M86.251	Subacute osteomyelitis, right femur
M86.252	Subacute osteomyelitis, left femur
M86.259	Subacute osteomyelitis, unspecified femur
M86.26	Subacute osteomyelitis, tibia and fibula
M86.261	Subacute osteomyelitis, right tibia and fibula
M86.262	Subacute osteomyelitis, left tibia and fibula
M86.269	Subacute osteomyelitis, unspecified tibia and fibula
M86.27	Subacute osteomyelitis, ankle and foot
M86.271	Subacute osteomyelitis, right ankle and foot
M86.272	Subacute osteomyelitis, left ankle and foot
M86.279	Subacute osteomyelitis, unspecified ankle and foot
M86.28	Subacute osteomyelitis, other site
M86.29	Subacute osteomyelitis, multiple sites
M86.3	Chronic multifocal osteomyelitis
M86.30	Chronic multifocal osteomyelitis, unspecified site
M86.31	Chronic multifocal osteomyelitis, shoulder
M86.311	Chronic multifocal osteomyelitis, right shoulder
M86.312	Chronic multifocal osteomyelitis, left shoulder
M86.319	Chronic multifocal osteomyelitis, unspecified shoulder
M86.32	Chronic multifocal osteomyelitis, humerus
M86.321	Chronic multifocal osteomyelitis, right humerus
M86.322	Chronic multifocal osteomyelitis, left humerus
M86.329	Chronic multifocal osteomyelitis, unspecified humerus
M86.33	Chronic multifocal osteomyelitis, radius and ulna
M86.331	Chronic multifocal osteomyelitis, right radius and ulna
M86.332	Chronic multifocal osteomyelitis, left radius and ulna
M86.339	Chronic multifocal osteomyelitis, unspecified radius and ulna
M86.34	Chronic multifocal osteomyelitis, hand
M86.341	Chronic multifocal osteomyelitis, right hand
M86.342	Chronic multifocal osteomyelitis, left hand
M86.349	Chronic multifocal osteomyelitis, unspecified hand
M86.35	Chronic multifocal osteomyelitis, femur
M86.351	Chronic multifocal osteomyelitis, right femur
M86.352	Chronic multifocal osteomyelitis, left femur
M86.359	Chronic multifocal osteomyelitis, unspecified femur
M86.36	Chronic multifocal osteomyelitis, tibia and fibula
M86.361	Chronic multifocal osteomyelitis, right tibia and fibula
M86.362	Chronic multifocal osteomyelitis, left tibia and fibula
M86.369	Chronic multifocal osteomyelitis, unspecified tibia and fibula
M86.37	Chronic multifocal osteomyelitis, ankle and foot
M86.371	Chronic multifocal osteomyelitis, right ankle and foot
M86.372	Chronic multifocal osteomyelitis, left ankle and foot
M86.379	Chronic multifocal osteomyelitis, unspecified ankle and foot
M86.38	Chronic multifocal osteomyelitis, other site
M86.39	Chronic multifocal osteomyelitis, multiple sites
M86.4	Chronic osteomyelitis with draining sinus
M86.40	Chronic osteomyelitis with draining sinus, unspecified site
M86.41	Chronic osteomyelitis with draining sinus, shoulder
M86.411	Chronic osteomyelitis with draining sinus, right shoulder
M86.412	Chronic osteomyelitis with draining sinus, left shoulder
M86.419	Chronic osteomyelitis with draining sinus, unspecified shoulder
M86.42	Chronic osteomyelitis with draining sinus, humerus
M86.421	Chronic osteomyelitis with draining sinus, right humerus
M86.422	Chronic osteomyelitis with draining sinus, left humerus
M86.429	Chronic osteomyelitis with draining sinus, unspecified humerus
M86.43	Chronic osteomyelitis with draining sinus, radius and ulna
M86.431	Chronic osteomyelitis with draining sinus, right radius and ulna
M86.432	Chronic osteomyelitis with draining sinus, left radius and ulna
M86.439	Chronic osteomyelitis with draining sinus, unspecified radius and ulna
M86.44	Chronic osteomyelitis with draining sinus, hand
M86.441	Chronic osteomyelitis with draining sinus, right hand
M86.442	Chronic osteomyelitis with draining sinus, left hand
M86.449	Chronic osteomyelitis with draining sinus, unspecified hand
M86.45	Chronic osteomyelitis with draining sinus, femur
M86.451	Chronic osteomyelitis with draining sinus, right femur
M86.452	Chronic osteomyelitis with draining sinus, left femur
M86.459	Chronic osteomyelitis with draining sinus, unspecified femur
M86.46	Chronic osteomyelitis with draining sinus, tibia and fibula
M86.461	Chronic osteomyelitis with draining sinus, right tibia and fibula
M86.462	Chronic osteomyelitis with draining sinus, left tibia and fibula
M86.469	Chronic osteomyelitis with draining sinus, unspecified tibia and fibula
M86.47	Chronic osteomyelitis with draining sinus, ankle and foot
M86.471	Chronic osteomyelitis with draining sinus, right ankle and foot
M86.472	Chronic osteomyelitis with draining sinus, left ankle and foot
M86.479	Chronic osteomyelitis with draining sinus, unspecified ankle and foot
M86.48	Chronic osteomyelitis with draining sinus, other site
M86.49	Chronic osteomyelitis with draining sinus, multiple sites
M86.5	Other chronic hematogenous osteomyelitis
M86.50	Other chronic hematogenous osteomyelitis, unspecified site
M86.51	Other chronic hematogenous osteomyelitis, shoulder
M86.511	Other chronic hematogenous osteomyelitis, right shoulder
M86.512	Other chronic hematogenous osteomyelitis, left shoulder
M86.519	Other chronic hematogenous osteomyelitis, unspecified shoulder
M86.52	Other chronic hematogenous osteomyelitis, humerus
M86.521	Other chronic hematogenous osteomyelitis, right humerus
M86.522	Other chronic hematogenous osteomyelitis, left humerus
M86.529	Other chronic hematogenous osteomyelitis, unspecified humerus
M86.53	Other chronic hematogenous osteomyelitis, radius and ulna
M86.531	Other chronic hematogenous osteomyelitis, right radius and ulna
M86.532	Other chronic hematogenous osteomyelitis, left radius and ulna
M86.539	Other chronic hematogenous osteomyelitis, unspecified radius and ulna
M86.54	Other chronic hematogenous osteomyelitis, hand
M86.541	Other chronic hematogenous osteomyelitis, right hand
M86.542	Other chronic hematogenous osteomyelitis, left hand
M86.549	Other chronic hematogenous osteomyelitis, unspecified hand
M86.55	Other chronic hematogenous osteomyelitis, femur
M86.551	Other chronic hematogenous osteomyelitis, right femur
M86.552	Other chronic hematogenous osteomyelitis, left femur
M86.559	Other chronic hematogenous osteomyelitis, unspecified femur
M86.56	Other chronic hematogenous osteomyelitis, tibia and fibula
M86.561	Other chronic hematogenous osteomyelitis, right tibia and fibula
M86.562	Other chronic hematogenous osteomyelitis, left tibia and fibula
M86.569	Other chronic hematogenous osteomyelitis, unspecified tibia and fibula
M86.57	Other chronic hematogenous osteomyelitis, ankle and foot
M86.571	Other chronic hematogenous osteomyelitis, right ankle and foot
M86.572	Other chronic hematogenous osteomyelitis, left ankle and foot
M86.579	Other chronic hematogenous osteomyelitis, unspecified ankle and foot
M86.58	Other chronic hematogenous osteomyelitis, other site
M86.59	Other chronic hematogenous osteomyelitis, multiple sites
M86.6	Other chronic osteomyelitis
M86.60	Other chronic osteomyelitis, unspecified site
M86.61	Other chronic osteomyelitis, shoulder
M86.611	Other chronic osteomyelitis, right shoulder
M86.612	Other chronic osteomyelitis, left shoulder
M86.619	Other chronic osteomyelitis, unspecified shoulder
M86.62	Other chronic osteomyelitis, humerus
M86.621	Other chronic osteomyelitis, right humerus
M86.622	Other chronic osteomyelitis, left humerus
M86.629	Other chronic osteomyelitis, unspecified humerus
M86.63	Other chronic osteomyelitis, radius and ulna
M86.631	Other chronic osteomyelitis, right radius and ulna
M86.632	Other chronic osteomyelitis, left radius and ulna
M86.639	Other chronic osteomyelitis, unspecified radius and ulna
M86.64	Other chronic osteomyelitis, hand
M86.641	Other chronic osteomyelitis, right hand
M86.642	Other chronic osteomyelitis, left hand
M86.649	Other chronic osteomyelitis, unspecified hand
M86.65	Other chronic osteomyelitis, thigh
M86.651	Other chronic osteomyelitis, right thigh
M86.652	Other chronic osteomyelitis, left thigh
M86.659	Other chronic osteomyelitis, unspecified thigh
M86.66	Other chronic osteomyelitis, tibia and fibula
M86.661	Other chronic osteomyelitis, right tibia and fibula
M86.662	Other chronic osteomyelitis, left tibia and fibula
M86.669	Other chronic osteomyelitis, unspecified tibia and fibula
M86.67	Other chronic osteomyelitis, ankle and foot
M86.671	Other chronic osteomyelitis, right ankle and foot
M86.672	Other chronic osteomyelitis, left ankle and foot
M86.679	Other chronic osteomyelitis, unspecified ankle and foot
M86.68	Other chronic osteomyelitis, other site
M86.69	Other chronic osteomyelitis, multiple sites
M86.8	Other osteomyelitis
M86.8x	Other osteomyelitis
M86.8x0	Other osteomyelitis, multiple sites
M86.8x1	Other osteomyelitis, shoulder
M86.8x2	Other osteomyelitis, upper arm
M86.8x3	Other osteomyelitis, forearm
M86.8x4	Other osteomyelitis, hand
M86.8x5	Other osteomyelitis, thigh
M86.8x6	Other osteomyelitis, lower leg
M86.8x7	Other osteomyelitis, ankle and foot
M86.8x8	Other osteomyelitis, other site
M86.8x9	Other osteomyelitis, unspecified sites
M86.9	Osteomyelitis, unspecified
Genitourinary tract infections
N30.0	Acute cystitis
N30.00	Acute cystitis without hematuria
N30.01	Acute cystitis with hematuria
N30.9	Cystitis, unspecified
N30.90	Cystitis, unspecified without hematuria
N30.91	Cystitis, unspecified with hematuria
N39.0	Urinary tract infection, site not specified
O03.38	Urinary tract infection following incomplete spontaneous abortion
O03.88	Urinary tract infection following complete or unspecified spontaneous abortion
O04.88	Urinary tract infection following (induced) termination of pregnancy
O07.38	Urinary tract infection following failed attempted termination of pregnancy
O23.0	Infections of kidney in pregnancy
O23.00	Infections of kidney in pregnancy, unspecified trimester
O23.01	Infections of kidney in pregnancy, first trimester
O23.02	Infections of kidney in pregnancy, second trimester
O23.03	Infections of kidney in pregnancy, third trimester
O23.1	Infections of bladder in pregnancy
O23.10	Infections of bladder in pregnancy, unspecified trimester
O23.11	Infections of bladder in pregnancy, first trimester
O23.12	Infections of bladder in pregnancy, second trimester
O23.13	Infections of bladder in pregnancy, third trimester
O23.2	Infections of urethra in pregnancy
O23.20	Infections of urethra in pregnancy, unspecified trimester
O23.21	Infections of urethra in pregnancy, first trimester
O23.22	Infections of urethra in pregnancy, second trimester
O23.23	Infections of urethra in pregnancy, third trimester
O23.3	Infections of other parts of urinary tract in pregnancy
O23.30	Infections of other parts of urinary tract in pregnancy, unspecified trimester
O23.31	Infections of other parts of urinary tract in pregnancy, first trimester
O23.32	Infections of other parts of urinary tract in pregnancy, second trimester
O23.33	Infections of other parts of urinary tract in pregnancy, third trimester
O23.4	Unspecified infection of urinary tract in pregnancy
O23.40	Unspecified infection of urinary tract in pregnancy, unspecified trimester
O23.41	Unspecified infection of urinary tract in pregnancy, first trimester
O23.42	Unspecified infection of urinary tract in pregnancy, second trimester
O23.43	Unspecified infection of urinary tract in pregnancy, third trimester
O23.9	Unspecified genitourinary tract infection in pregnancy
O23.90	Unspecified genitourinary tract infection in pregnancy, unspecified trimester
O23.91	Unspecified genitourinary tract infection in pregnancy, first trimester
O23.92	Unspecified genitourinary tract infection in pregnancy, second trimester
O23.93	Unspecified genitourinary tract infection in pregnancy, third trimester
O86.2	Urinary tract infection following delivery
O86.20	Urinary tract infection following delivery, unspecified
O86.21	Infection of kidney following delivery
O86.22	Infection of bladder following delivery
O86.29	Other urinary tract infection following delivery
P39.3	Neonatal urinary tract infection
Infectious disorder of joint
M00.9	Pyogenic arthritis, unspecified
Lower respiratory infection
J15.9	Unspecified bacterial pneumonia
J18.9	Pneumonia, unspecified organism
J22	Unspecified acute lower respiratory infection
Skin and skin structure infection
H05.01	Cellulitis of orbit
H05.011	Cellulitis of right orbit
H05.012	Cellulitis of left orbit
H05.013	Cellulitis of bilateral orbits
H05.019	Cellulitis of unspecified orbit
H60.1	Cellulitis of external ear
H60.10	Cellulitis of external ear, unspecified ear
H60.11	Cellulitis of right external ear
H60.12	Cellulitis of left external ear
H60.13	Cellulitis of external ear, bilateral
K12.2	Cellulitis and abscess of mouth
L03	Cellulitis and acute lymphangitis
L03.0	Cellulitis and acute lymphangitis of finger and toe
L03.01	Cellulitis of finger
L03.011	Cellulitis of right finger
L03.012	Cellulitis of left finger
L03.019	Cellulitis of unspecified finger
L03.03	Cellulitis of toe
L03.031	Cellulitis of right toe
L03.032	Cellulitis of left toe
L03.039	Cellulitis of unspecified toe
L03.1	Cellulitis and acute lymphangitis of other parts of limb
L03.11	Cellulitis of other parts of limb
L03.111	Cellulitis of right axilla
L03.112	Cellulitis of left axilla
L03.113	Cellulitis of right upper limb
L03.114	Cellulitis of left upper limb
L03.115	Cellulitis of right lower limb
L03.116	Cellulitis of left lower limb
L03.119	Cellulitis of unspecified part of limb
L03.2	Cellulitis and acute lymphangitis of face and neck
L03.21	Cellulitis and acute lymphangitis of face
L03.211	Cellulitis of face
L03.22	Cellulitis and acute lymphangitis of neck
L03.221	Cellulitis of neck
L03.3	Cellulitis and acute lymphangitis of trunk
L03.31	Cellulitis of trunk
L03.311	Cellulitis of abdominal wall
L03.312	Cellulitis of back [any part except buttock]
L03.313	Cellulitis of chest wall
L03.314	Cellulitis of groin
L03.315	Cellulitis of perineum
L03.316	Cellulitis of umbilicus
L03.317	Cellulitis of buttock
L03.319	Cellulitis of trunk, unspecified
L03.8	Cellulitis and acute lymphangitis of other sites
L03.81	Cellulitis of other sites
L03.811	Cellulitis of head [any part, except face]
L03.818	Cellulitis of other sites
L03.9	Cellulitis and acute lymphangitis, unspecified
L03.90	Cellulitis, unspecified
L08.9	Local infection of the skin and subcutaneous tissue, unspecified
N48.22	Cellulitis of corpus cavernosum and penis
Staphylococcal pneumonia
J15.2	Pneumonia due to staphylococcus
J15.20	Pneumonia due to staphylococcus, unspecified
J15.21	Pneumonia due to staphylococcus aureus
J15.211	Pneumonia due to methicillin susceptible staphylococcus aureus
J15.212	Pneumonia due to methicillin resistant staphylococcus aureus
J15.29	Pneumonia due to other staphylococcus
Staphylococcus aureus endocarditis
B95.6	Staphylococcus aureus as the cause of diseases classified elsewhere
B95.61	Methicillin susceptible staphylococcus aureus infection as the cause of diseases classified elsewhere
I33.0	Acute and subacute infective endocarditis
Streptococcal endocarditis
B95.0	Streptococcus, group a, as the cause of diseases classified elsewhere
B95.1	Streptococcus, group b, as the cause of diseases classified elsewhere
B95.3	Streptococcus pneumoniae as the cause of diseases classified elsewhere
B95.4	Other streptococcus as the cause of diseases classified elsewhere
B95.5	Unspecified streptococcus as the cause of diseases classified elsewhere
I33.0	Acute and subacute infective endocarditis
Streptococcal pneumonia
J13	Pneumonia due to streptococcus pneumoniae
J15.3	Pneumonia due to streptococcus, group B
J15.4	Pneumonia due to other streptococci